Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman B, Wanner C, Lachin JM
New England Journal of Medicine · 2015
This randomized controlled trial evaluates the intervention under study in relation to the primary clinical outcome. Includes 7,020 participants. Evidence level: Ia.
循证研究：恩格列净心血管结局研究
Key facts at a glance
- DOI
- 10.1056/NEJMoa1504720
- PMID
- 26378978
- Journal
- New England Journal of Medicine
- Year
- 2015
- Study type
- rct
- Evidence level
- Ia
- Sample size
- 7020
- Intervention
- Empagliflozin 10mg/25mg vs 安慰剂
- Primary outcome
- 心血管死亡、MI、卒中复合终点 (3P-MACE)
- Open access
- false
Study Overview
This randomized controlled trial enrolled 7,020 participants and examined the primary clinical outcome.
Key Findings
Results regarding the primary clinical outcome are presented.
Clinical Conclusions
See original publication for detailed findings. Evidence level: Ia.
Abstract
"This randomized controlled trial enrolled 7,020 participants, investigating the effects of Empagliflozin 10mg/25mg vs 安慰剂 on 心血管死亡、MI、卒中复合终点 (3P-MACE).
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed October 18, 2026. · Read our editorial policy